Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Stage not disclosed · ActiveModality: bispecific antibody
Aliases AK112, SMT112
Target PD-1 / VEGF
Partnerships Akeso: in-license (Dec 2022, closed Jan 2023; expanded Jun 2024) covering US, Canada, Europe, Japan, Latin America, Middle East, Africa. Summit controls clinical development, regulatory filings, and commercial strategy in the Licensed Territory.
Indications
Oncology(Stage not disclosed)
Status note Novel potential first-in-class bispecific antibody combining PD-1 blockade with anti-VEGF in a single molecule; in clinical development in the Licensed Territory. Filing excerpts do not state specific trials, phases, or indications. Ridinilazole was divested via asset purchase agreement (Jun 2026) and is no longer a Summit asset.
Per-asset detail extracted from the 10-Q filed 2026-07-23. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Advanced Head and Neck Squamous Cell Carcinoma; Resectable Head and Neck Squamous Cell Carcinoma; Stage II Head and Neck Cutaneous Squamous Cell Carcinoma
Sponsor-matched active trials from ClinicalTrials.gov (5 as sponsor, 26 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.
Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 714 stocks.